Selection and utilization on the evaluation criterions of caco-2 cell model

Chinese Pharmaceutical Journal

Volumn 43, Issue 24, 2008, Pages

  Cai, Run Ian ^a   Wang, Min ^a   Qi, Yun ^a   Wang, Xiang Yan ^a   Xie, Chen ^a   Luo, Xiu Zhen ^a  

^a INSTITUTE OF MEDICINAL PLANT DEVELOPMENT   (China)

Author keywords

ALP; Caco 2 cell; P glycoprotein; TEER

Indexed keywords

ALKALINE PHOSPHATASE; FEXOFENADINE;

ARTICLE; BIOLOGICAL MODEL; CELL MEMBRANE PERMEABILITY; CELL SELECTION; CELL STRAIN CACO 2; CELL TRANSPORT; CONTROLLED STUDY; EFFUSION; ELECTRIC RESISTANCE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; INTESTINE ABSORPTION; VALIDATION STUDY;

EID: 60049094905     PISSN: 10012494     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. WANG M, QI Y. Recent progress in Caco-2 cell model and its application in drug absorption[J]. Chin Pharm J, 2007, 42(16):1201-1204.
2. SUSSMAN N L, ELIAKIM R, RUBIN D, et al. Intestinal alkaline phosphatase is secreted bidirectionally from villous enterocytes[J]. Am J Physiol, 1989, 257(1 Pt 1): 14-23.
3. YU H, COOK T J, SINKO P J. Evidence for diminished functional expression of intestinal transporters in Caco-2 cell monolayers at high passahes[J].Pharm Res, 1997, 14(6):757-762.
4. MARKOWSKA M, OBERLE R, JUZWIN S, et al. Optimizing Caco-2 cell monolayers to increase throughput in drug intestinal absorption analysis[J]. J Pharmacol Toxicol Methods, 2001, 46 (1):51-55.
5. YU H, SINKO P J. Influence of the microporous substratum and hydrodynamics on resistances to drug transport in cell culture systems: calculation of intrinsic transport parameters [J]. J Pharm Sci, 1997, 86(12):1448-1457.
6. TUCKER S P, MELSEN L R, COMPANS R W. Migration of polarized epithelial cells through permeable membrane substrates of defined pore size [J]. Eur J Cell Biol, 1992, 58(2):280-290.
7. GEYS J, NEMERY B, HOET P H. Optimisation of culture conditions to develop an in vitro pulmonary permeability model [J]. Toxicol In Vitro, 2007, 2] (7):1215-1219.
8. NARAI A, ARAI S, SHKIMIZU M. Rapid decrease in transep-ithelial electrical resistance of human intestinal Caco-2 cell monolayers by cytotoxic membrane perturbents [J]. Toxicol In Vitro, 1997, 11:347-354.
9. AIBA T, ISHIDA K, YOSHINAGA M, et al. Pharmacokinetic characterization of transcellular transport and drug interaction of digoxin in Caco-2 cell monolayers [J]. Biol Pharm Bull, 2005, 28(1):114-119.
10. KONSOULA R, BARILE F A. Correlation of in vitro cytotoxicity with paracellular permeability in Caco-2 cell [J]. Toxicol In Vitro, 2005, 19(5):675-684.
11. HILGERS A R, CONRADI R A, BURTON P S. Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa[J]. Pharm Res, 1990, 7(9):902-910.
12. ROBINSON J M, KAMOVSKY M J. Ultrastructural localization of several phosphatases with cerium [J]. J Histochem Cytochem, 1983, 31(10):1197-1208.
13. YANG X W, YANG X D, WANG Y, et al. Establishment of Caco-2 cell monolayer model and standard operation procedure for assessing intestinal absorption of chemical components of traditional Chinese medicine[ J]. J Chin Integr Med, 2007, 5(6):634-641.
14. LENG W, ZHENG Y, LI S P, et al. Study on absorption mechan- isms of Zedoary Turmeric Oil by Caco-2 cell model[J]. Chin Pham J., 2007, 42(16):1228-1232.
15. GRES M C, JULIAN B, BOURRIE M, et al. Correlation between oral drug absorption in humans, and apparent drug permeability in TC-7 cell, a human epithelial intestinal cell line: comparison with the parental Caco-2 cell line[J].Pfearm Res, 1998, 15(5):726-733.
16. YEE S Y. In vitro permeability across Caco-2 cell (colonic) can perdict in vivo (small intestinal) absorption in man-fact or myth [J]. Pharm Res, 1997, 14 (6): 763-766.
17. JUNC S J, CHOI S O, UMA S Y. Prediction of the permeability of drugs through study on quantitative structure permeability relationship [J]. J Pharm Biomed Anal, 2006, 41 (2): 469475.
18. ASANO T, ISHIHARA K, MOROTA T, et al. Permeability of the flavonoids liquiritigenin and its glycosides in licorice roots and davidigenin, a hydrogenated metabolite of liquiritigenin, using human intestinal cell line Caco-2 [J]. J Ethnopharmacol, 2003, 89 (2-3): 285-289.
19. MASUNGI C, BORREMANS C, WILEMS B, et al. Usefulness of a novel Caco-2 cell perfusion system. I. In vitro prediction of the absorption potential of passively diffused compounds [J]. J Pharm Sci, 2004, 93 (10):2507-2521.
20. KONISHI Y, HAGIWARA K, SHIMIZU M. Transepithelial tran- sport of fluorescein in Caco-2 cell monolayers and use of such transport in in vitro evaluation of phenolic acid availability [J]. Biosci Biotechnol Biochem, 2002, 66 (11): 2449-2457.
21. PERLOFF MD, VONMOLTKE L L, GREENBLATT D J. Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir [J], J Clin Pharmacol, 2002, 42 (11): 1269-1274.
22. LEHMANN T, KOHLER C, WEIDAUER E, et al. Expression of MRP1 and related transporters in human lung cells in culture [J]. Toxicology, 2001, 167 (1):59-72.
23. GUAN S, ZHAO L Z, CHEN J, et al. Establishment and value of Caco-2 cell model [J]. Shandong Med J, 2005, 45 (26): 1-3.
24. POLLI J W, WRING S A, HUMPHREYS J E, et al. Rational use of in vitro P-glycoprotein assays in drug discovery [J]. J Pharmacol Exp Ther, 2001, 299 (1): 620-628.